CELU Celularity Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1752828 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.5%
TTM net income YoY34.7%
TTM EPS YoY43.2%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—
Margins
Gross margin55.1%
Operating margin-105.8%
Net margin-165.2%
FCF margin—
EBITDA margin-90.8%
Returns
ROE-6,367.2%
ROA-57.6%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets121.2%
Debt / equity—
Current ratio0.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.03x
Accruals ratio-55.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $26.55M | $54.22M | $22.77M | $17.98M | $21.34M |
| Cost of revenue | $20.07M | $14.99M | $16.02M | — | — |
| Gross profit | $6.48M | $39.23M | $6.75M | -$1.69M | $11.68M |
| R&D expense | $15.03M | $17.39M | $30.46M | $78.36M | $88.35M |
| SG&A expense | $51.27M | $58.64M | $50.58M | $66.02M | $71.34M |
| Operating income | -$61.31M | -$38.36M | -$192.29M | -$25.60M | -$109.06M |
| Pretax income | -$91.71M | -$57.89M | -$196.28M | $14.21M | -$100.10M |
| Income tax | $3,000 | — | $10,000 | $13,000 | $20,000 |
| Net income | -$91.72M | -$57.89M | -$196.29M | $14.19M | -$100.12M |
| EBITDA | -$54.01M | -$30.44M | -$182.96M | -$16.16M | -$100.24M |
| EPS (basic) | -3.59 | -2.64 | -11.02 | 1.01 | -1.49 |
| EPS (diluted) | -3.59 | -2.64 | -11.02 | 0.95 | -1.49 |
| Weighted avg. shares (diluted) | 25.60M | 21.89M | 17.81M | 14.98M | 67.06M |
| Balance sheet | |||||
| Cash & equivalents | $6.17M | $10.98M | $10.16M | $28.80M | $52.08M |
| Receivables | $4.65M | — | — | — | — |
| Inventory | $571,000 | $5.41M | $5.75M | $5.31M | $9.55M |
| Current assets | $12.32M | $20.56M | $19.79M | $33.50M | $59.10M |
| PP&E, net | $55.80M | $61.60M | $67.83M | $75.66M | $90.62M |
| Goodwill | $7.35M | $7.35M | $7.35M | $119.69M | $123.30M |
| Intangibles | $7.76M | $9.25M | $11.00M | $120.99M | $123.19M |
| Total assets | $107.33M | $132.68M | $143.89M | $401.07M | $414.13M |
| Current liabilities | $80.76M | $53.68M | $67.30M | $62.09M | $26.23M |
| Short-term debt | — | — | $39.24M | $37.60M | — |
| Long-term debt | $33.81M | — | — | — | — |
| Total debt | $33.81M | — | — | — | — |
| Total liabilities | $145.39M | $123.84M | $102.93M | $202.16M | $314.71M |
| Shareholders' equity | -$38.06M | $8.84M | $40.96M | $198.90M | $99.42M |
| Net debt | $27.64M | — | — | — | — |
| Shares outstanding | 28.84M | 22.55M | 19.38M | 14.89M | 124.31M |
| Cash flow statement | |||||
| Operating cash flow | -$13.25M | -$6.40M | -$38.69M | -$137.88M | -$110.10M |
| Capital expenditure | — | $161,000 | $1.05M | $5.24M | $6.20M |
| Free cash flow | — | -$6.56M | -$39.73M | -$143.11M | -$116.30M |
| Investing cash flow | — | $514,000 | -$4.05M | -$5.24M | -$5.90M |
| Financing cash flow | $18.65M | $6.70M | $24.09M | $119.84M | $98.56M |
| Depreciation & amortization | $7.29M | $7.92M | $9.32M | $9.44M | $8.82M |
| Stock-based compensation | $10.64M | $11.57M | $0 | $15.86M | $40.01M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.